Dissecting modes of action of non-genotoxic carcinogens in primary mouse hepatocytes

Arch Toxicol. 2012 Nov;86(11):1717-27. doi: 10.1007/s00204-012-0883-6. Epub 2012 Jun 19.

Abstract

Under REACH, the European Community Regulation on chemicals, the testing strategy for carcinogenicity is based on in vitro and in vivo genotoxicity assays. Given that non-genotoxic carcinogens are negative for genotoxicity and chronic bioassays are no longer regularly performed, this class of carcinogens will go undetected. Therefore, test systems detecting non-genotoxic carcinogens, or even better their modes of action, are required. Here, we investigated whether gene expression profiling in primary hepatocytes can be used to distinguish different modes of action of non-genotoxic carcinogens. For this, primary mouse hepatocytes were exposed to 16 non-genotoxic carcinogens with diverse modes of action. Upon profiling, pathway analysis was performed to obtain insight into the biological relevance of the observed changes in gene expression. Subsequently, both a supervised and an unsupervised comparison approach were applied to recognize the modes of action at the transcriptomic level. These analyses resulted in the detection of three of eight compound classes, that is, peroxisome proliferators, metalloids and skin tumor promotors. In conclusion, gene expression profiles in primary hepatocytes, at least in rodent hepatocytes, appear to be useful to detect some, certainly not all, modes of action of non-genotoxic carcinogens.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinogens / administration & dosage
  • Carcinogens / metabolism
  • Carcinogens / pharmacology
  • Carcinogens / toxicity*
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Gene Expression Profiling*
  • Hepatocytes / drug effects*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mutagens / toxicity
  • Toxicity Tests / methods*

Substances

  • Carcinogens
  • Mutagens